+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia



Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia



Journal of Lipid Research 57(11): 2073-2087



Atherogenic mixed dyslipidemia associates with oxidative stress and defective HDL antioxidative function in metabolic syndrome (MetS). The impact of statin treatment on the capacity of HDL to inactivate LDL-derived, redox-active phospholipid hydroperoxides (PCOOHs) in MetS is indeterminate. Insulin-resistant, hypertriglyceridemic, hypertensive, obese males were treated with pitavastatin (4 mg/day) for 180 days, resulting in marked reduction in plasma TGs (-41%) and LDL-cholesterol (-38%), with minor effects on HDL-cholesterol and apoAI. Native plasma LDL (baseline vs. 180 days) was oxidized by aqueous free radicals under mild conditions in vitro either alone or in the presence of the corresponding pre- or poststatin HDL2 or HDL3 at authentic plasma mass ratios. Lipidomic analyses revealed that statin treatment i) reduced the content of oxidizable polyunsaturated phosphatidylcholine (PUPC) species containing DHA and linoleic acid in LDL; ii) preferentially increased the content of PUPC species containing arachidonic acid (AA) in small, dense HDL3; iii) induced significant elevation in the content of phosphatidylcholine and phosphatidylethanolamine (PE) plasmalogens containing AA and DHA in HDL3; and iv) induced formation of HDL3 particles with increased capacity to inactivate PCOOH with formation of redox-inactive phospholipid hydroxide. Statin action attenuated LDL oxidability Concomitantly, the capacity of HDL3 to inactivate redox-active PCOOH was enhanced relative to HDL2, consistent with preferential enrichment of PE plasmalogens and PUPC in HDL3.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058900360

Download citation: RISBibTeXText

PMID: 27581680

DOI: 10.1194/jlr.p068585


Related references

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Hdl2- and Hdl3- Mediated Transport of Sphingosine-1-phosphate in Mixed Dyslipidemia: Effect of Statin Treatment. Atherosclerosis Supplements 32: 148-149, 2018

A time-resolved fluorescence spectroscopic comparison of phospholipid bilayers containing mixed chain polyunsaturated phospholipids. Biophysical Journal 64(2 Part 2): A68, 1993

HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arteriosclerosis Thrombosis and Vascular Biology 29(12): 2169-2175, 2009

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuro Endocrinology Letters 33(Suppl. 2): 87-92, 2012

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. Journal of Clinical Lipidology 12(3): 784-800.E4, 2018

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. International Journal of Cardiology 248: 355-360, 2017

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014

Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atherosclerosis. Supplements 14(2): 237-242, 2013

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. Journal of Clinical Lipidology 12(3): 810-821.E1, 2018

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy. Clinica e Investigacion en Arteriosclerosis 28(2): 87-93, 2017

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26(12): 2833-2839, 2010

Incorporation of polyunsaturated fatty acids into plasmalogens compared to other phospholipids of cultured glioma cells is more dependent on chain length than on selectivity between n 3 and n 6 families. Biochimica et Biophysica Acta 1044(3): 349-356, 1990

Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. Journal of Cardiology 74(3): 290-295, 2019

Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia. Lipids in Health and Disease 14: 67, 2015